Interim reports

Here you will find Lundbeck's interim reports since the time we were introduced on the Copenhagen Stock Exchange.

Interim report for the first quarter of 2008

Lundbeck’s interim report for the first quarter of 2008 shows continuing strong growth in consolidated revenue distributed on the company’s new products as well as on the regions. Lundbeck retains its financial forecasts for revenue and profit from operations which the company announced in connection with the release of its annual report for 2007.

Revenue, earnings and investments
• Revenue: DKK 2,882 million (+12% and +14% at CER)
• Profit from operations (EBIT): DKK 924 million (+41%)
• Investments: DKK 138 million

Revenue by regions and products
• Europe: DKK 1,516 million (+14% and +15% at CER)
• International Markets: DKK 651 million (+18% and +24% at CER)
• USA: DKK 661 million (+5% and +6% at CER)

• Cipralex®: DKK 1,216 million (+23% and +26% at CER)
• Lexapro®: DKK 661 million (+5% and +7% at CER)
• Ebixa®: DKK 457 million (+17% and +18% at CER)
• Azilect®: DKK 54 million (+61% and +62% at CER)

The following Lundbeck interim reports are available as Adobe PDF files.

You can download the free Adobe Acrobat Reader plug-in at: www.adobe.com

Interim report for the first quarter of 2008 (PDF, 196 Kb) Financial figures Q1 2008

Interim report for the third quarter of 2007 (PDF, 255 Kb)

Interimreport for the second quarter of 2007 (PDF 224 Kb)

Interimreport for the first quarter of 2007 (PDF 220 Kb)

Interim report for the third quarter of 2006 (PDF, 501 Kb)

Interim report for the second quarter of 2006 (PDF, 262 Kb)

Interim report for the first quarter of 2006 (PDF, 247 Kb)

Interim report for the third quarter of 2005 (PDF, 222 Kb)

Interim report for the second quarter of 2005 (PDF, 530 Kb)

Interim report for the first quarter of 2005 (PDF, 291 Kb)